Patient characteristics
| Characteristics . | Total (n = 53) . | Cohort 1 (n = 21) . | Cohort 2 (n = 15) . | Cohort 3 (n = 17) . | P . |
|---|---|---|---|---|---|
| Median age (range) | 62 (19-88) | 63 (47-88) | 69 (44-78) | 57 (19-76) | .042 |
| Male, n (%) | 27 (51%) | 11 (52%) | 7 (47%) | 9 (53%) | .9 |
| Prior no. of therapies, median (range) | 3 (0-11) | 2 (0-9) | 4 (1-11) | 4 (1-8) | <.001 |
| Prior transplants, n (%) | 12 (23%) | 3 (14%) | 3 (20%) | 6 (35%) | .3 |
| Autologous | 6 (11%) | 1 (5%) | 2 (13%) | 3 (18%) | .4 |
| Allogeneic | 6 (11%) | 2 (10%) | 1 (7%) | 3 (18%) | .6 |
| Race, n (%) | .5 | ||||
| White | 42 (79%) | 16 (76%) | 13 (87%) | 13 (76%) | |
| African American or Black | 5 (9%) | 1 (5%) | 1 (7%) | 3 (18%) | |
| Asian | 3 (6%) | 3 (14%) | 0 | 0 | |
| Unknown | 3 (6%) | 1 (5%) | 1 (7%) | 1 (6%) |
| Characteristics . | Total (n = 53) . | Cohort 1 (n = 21) . | Cohort 2 (n = 15) . | Cohort 3 (n = 17) . | P . |
|---|---|---|---|---|---|
| Median age (range) | 62 (19-88) | 63 (47-88) | 69 (44-78) | 57 (19-76) | .042 |
| Male, n (%) | 27 (51%) | 11 (52%) | 7 (47%) | 9 (53%) | .9 |
| Prior no. of therapies, median (range) | 3 (0-11) | 2 (0-9) | 4 (1-11) | 4 (1-8) | <.001 |
| Prior transplants, n (%) | 12 (23%) | 3 (14%) | 3 (20%) | 6 (35%) | .3 |
| Autologous | 6 (11%) | 1 (5%) | 2 (13%) | 3 (18%) | .4 |
| Allogeneic | 6 (11%) | 2 (10%) | 1 (7%) | 3 (18%) | .6 |
| Race, n (%) | .5 | ||||
| White | 42 (79%) | 16 (76%) | 13 (87%) | 13 (76%) | |
| African American or Black | 5 (9%) | 1 (5%) | 1 (7%) | 3 (18%) | |
| Asian | 3 (6%) | 3 (14%) | 0 | 0 | |
| Unknown | 3 (6%) | 1 (5%) | 1 (7%) | 1 (6%) |
| Subtype, n (%) . | Total (n=53) . | Cohort 1 (n=21) . | Cohort 2 (n=15) . | Cohort 3 (n=17) . | P . |
|---|---|---|---|---|---|
| PTCL, NOS | 12 (23%) | 2 (10%) | 5 (33%) | 5 (29%) | .2 |
| T-PLL | 8 (15%) | 7 (33%) | 1 (7%) | 0 | .007 |
| AITL/TFH | 9 (17%) | 2 (10%) | 5 (33%) | 2 (12%) | .2 |
| T-LGL | 5 (9%) | 3 (14%) | 0 | 2 (12%) | .4 |
| ALCL* | 4 (8%) | 2 (10%) | 0 | 2 (12%) | .5 |
| ATLL | 3 (6%) | 0 | 0 | 3 (18%) | .049 |
| MF† | 7 (13%) | 2 (10%) | 3 (20%) | 2 (12%) | .7 |
| γ/δ TCLs‡ | 4 (8%) | 3 (14%) | 0 (0%) | 1 (6%) | .4 |
| SPTCL | 1 (2%) | 0 | 1 (7%) | 0 | .3 |
| Subtype, n (%) . | Total (n=53) . | Cohort 1 (n=21) . | Cohort 2 (n=15) . | Cohort 3 (n=17) . | P . |
|---|---|---|---|---|---|
| PTCL, NOS | 12 (23%) | 2 (10%) | 5 (33%) | 5 (29%) | .2 |
| T-PLL | 8 (15%) | 7 (33%) | 1 (7%) | 0 | .007 |
| AITL/TFH | 9 (17%) | 2 (10%) | 5 (33%) | 2 (12%) | .2 |
| T-LGL | 5 (9%) | 3 (14%) | 0 | 2 (12%) | .4 |
| ALCL* | 4 (8%) | 2 (10%) | 0 | 2 (12%) | .5 |
| ATLL | 3 (6%) | 0 | 0 | 3 (18%) | .049 |
| MF† | 7 (13%) | 2 (10%) | 3 (20%) | 2 (12%) | .7 |
| γ/δ TCLs‡ | 4 (8%) | 3 (14%) | 0 (0%) | 1 (6%) | .4 |
| SPTCL | 1 (2%) | 0 | 1 (7%) | 0 | .3 |
AITL/TFH, angioimmunoblastic T-cell lymphoma and other T-follicular helper lymphomas; ATLL, adult T-cell lymphoma lymphoma/leukemia; γ/δ TCL, γ/δ T-cell lymphomas; SPTCL, subcutaneous panniculitis-like T-cell lymphoma.
ALCL includes systemic ALK− ALCL (n = 3) and primary cutaneous ALCL (n = 1).
2 patients with MF had large cell transformation.
γ/δ TCLs included hepatosplenic T-cell lymphoma (n = 2), monomorphic epitheoliotropic intestinal T-cell lymphoma (n = 1), and primary cutaneous γ/δ T-cell lymphoma (n = 1).